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Abstract
Objective: To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyo-
trophic lateral sclerosis (ALS). Methods: Patients (2 years since diagnosis) with slow upright vital capacity (SVC) of
60% were randomized 1:1:1:1 to reldesemtiv 150, 300, or 450mg twice daily (bid) or placebo; active treatment was 12
weeks with 4-week follow-up. Primary endpoint was change in percent predicted SVC at 12 weeks; secondary measures
included ALS Functional Rating Scale-Revised (ALSFRS-R) and muscle strength mega-score. Results: Patients
(N¼458) were enrolled; 85% completed 12-week treatment. The primary analysis failed to reach statistical significance
(p¼ 0.11); secondary endpoints showed no statistically significant effects (ALSFRS-R, p¼0.09; muscle strength mega-
score, p¼ 0.31). Post hoc analyses pooling all active reldesemtiv-treated patients compared against placebo showed trends
toward benefit in all endpoints (progression rate for SVC, ALSFRS-R, and muscle strength mega-score (nominal p val-
ues of 0.10, 0.01 and 0.20 respectively)). Reldesemtiv was well tolerated, with nausea and fatigue being the most common
side effects. A dose-dependent decrease in estimated glomerular filtration rate was noted, and transaminase elevations
were seen in approximately 5% of patients. Both hepatic and renal abnormalities trended toward resolution after study
drug discontinuation. Conclusions: Although the primary efficacy analysis did not demonstrate statistical significance,
there were trends favoring reldesemtiv for all three endpoints, with effect sizes generally regarded as clinically important.
Tolerability was good; modest hepatic and renal abnormalities were reversible. The impact of reldesemtiv on patients with
ALS should be assessed in a pivotal Phase 3 trial. (ClinicalTrials.gov Identifier: NCT03160898)
Keywords: Randomized clinical trial, amyotrophic lateral sclerosis, reldesemtiv
Introduction
Fast skeletal muscle troponin activators (FSTAs) sen-
sitize the sarcomere to calcium and increase muscle
force. This mechanism is of potential relevance in
amyotrophic lateral sclerosis (ALS) and other neuro-
muscular disorders that cause weakness and muscle
fatigue. A first-generation FSTA, tirasemtiv, showed
promise in phase 2a studies in ALS (1–3) and myas-
thenia gravis (4). Additionally, a large phase 2b study
of tirasemtiv in ALS suggested efficacy by slowing the
rates of decline of slow vital capacity (SVC) and iso-
metric muscle strength (5). Dizziness was the most
common adverse event (AE) of tirasemtiv, which
often resulted in dropout from the study. A subse-
quent phase 3 trial was designed to reduce the inci-
dence of early termination. The trial failed to show a
statistically significant effect on any endpoint; how-
ever, large numbers of dose-dependent, early termi-
nations due to poor tolerability still occurred and
confounded the interpretation of the trial results (6).
Reldesemtiv is a second generation FSTA derived
from a different chemical scaffold than tirasemtiv,
with limited penetration of the blood-brain barrier
to minimize off-target effects. A single-dose study in
healthy participants showed that reldesemtiv had a
greater pharmacodynamic effect on muscle force
generation with submaximal nerve stimulation fre-
quencies than tirasemtiv, and central nervous system
side effects were not noted (7, 8). Based on these
data, the phase 2b trial, FORTITUDE-ALS
(Functional Outcomes in a Randomized Trial of
Investigational Treatment with CK-2127107 to
Understand Decline in Endpoints – in ALS), was
designed to study the safety, tolerability, and pre-
liminary efficacy of three doses of reldesemtiv versus
placebo in patients with ALS.
Methods
Patients
This randomized, double-blind, multicentre, dose-
ranging, placebo-controlled, phase 2b trial
recruited patients from 65 clinical trial sites in the
United States, Canada, Ireland, Spain, the
Netherlands, and Australia. Patients were between
18 and 80 years of age, and diagnosed within 24
months with possible, laboratory-supported prob-
able, probable, or definite ALS according to the
revised El Escorial criteria (9). An upright SVC
60% predicted for age, height, sex, and ethnic
group at screening was required for inclusion.
Patients on riluzole must have taken it for 30
days prior to screening. Following protocol amend-
ment 2 (August 10, 2017), patients on edaravone
were eligible to enroll in the trial and must have
completed 2 cycles prior to screening. Exclusion
criteria included prior use of reldesemtiv or tirasem-
tiv or receipt of stem cell or gene therapy for ALS.
Standard protocol approvals, registrations, and
patient consents
All patients provided written informed consent,
and all sites received institutional review board
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approvals prior to enrollment. The trial was con-
ducted in accordance with the Declaration of
Helsinki and Good Clinical Practice.
FORTITUDE-ALS was registered with
ClinicalTrials.gov (NCT03160898) and was con-
ducted between August 2017 and March 2019.
Trial design and assessments
After a screening period of up to 14 days, eligible
patients were randomized via an interactive web
response system 1:1:1:1 to placebo or reldesemtiv
(CK-2127107) oral tablets 150, 300, or 450mg
twice daily (bid) stratified by use and nonuse of
riluzole and edaravone. All site clinical staff (inves-
tigators, pharmacists, support staff) involved with
the study, patients, and the sponsor were blinded
to treatment assignment. Study medication was to
be taken twice daily, approximately 12±2hours
apart and within 2 h following a meal. The active
treatment period was 12 weeks with assessments at
day 1 and weeks 2, 4, 8, and 12 and at a follow-
up visit 4 weeks after the last dose.
The primary endpoint was the change in per-
cent predicted SVC, from baseline to week 12. To
qualify for the study, at screening in addition to
having a minimum SVC of 60% of predicted based
upon the global lung initiative values (10), patients
also had to demonstrate less than 10% variability
of the two highest values in five or fewer attempts.
All flow volume loops were reviewed by blinded
pulmonologists. Secondary endpoints included
changes in the ALS Functional Rating Scale-
Revised (ALSFRS-R) Total Score and the slope of
muscle strength mega-score from baseline to week
12 measured by hand-held dynamometer and by
hand grip dynamometry. The following muscle
groups were tested bilaterally: elbow flexion, wrist
extension, first dorsal interosseous, hip flexion,
knee extension, and ankle dorsiflexion. Plasma
concentrations for each dose level of reldesemtiv
were assessed at day 1 and weeks 2, 4, 8, and 12.
Safety assessments included the incidence and
severity of treatment-emergent AEs (TEAEs) as
recorded using the Medical Dictionary for
Regulatory Activities version 20.0 as well as vital
signs, clinical laboratory tests, electrocardiograms,
Beck Depression Inventory-Fast Screen, Ashworth
Score, and physical and neurological examinations.
Statistical analysis
The full analysis set (FAS) consisted of all
randomized patients who received any study drug
and had a baseline and at least one post-baseline
efficacy assessment during the double-blind period.
The safety analysis set included all randomized
patients who received any study drug. The
pharmacokinetics analysis consisted of all
randomized patients with at least one evaluable
plasma concentration of reldesemtiv.
The primary efficacy analysis hypothesis was
that reldesemtiv had a beneficial and dose-depend-
ent effect on function as measured by the change
from baseline to week 12 in the percent predicted
SVC. To test this hypothesis, a mixed model for
repeated measures (MMRM) with a contrast (5,
1, 3, 3) for the placebo and reldesemtiv 150mg
bid, 300mg bid, and 450mg bid dose groups was
used (SASVR version 9.4 or greater). The response
variable in the model was the change in the per-
cent predicted SVC from baseline to each post-
baseline visit. The model also included the terms
of treatment, baseline value, pooled site, visit, and
randomization stratification factors of baseline rilu-
zole and/or edaravone use/nonuse, as well as treat-
ment-by-visit and baseline-by-visit interactions. An
unstructured variance-covariance structure was
used in the model. The model included all
observed data points from baseline to week 12 for
all patients in the FAS with missing values main-
tained as missing and imputed missing data under
the missing at random paradigm and provided the
estimates at week 12 from the observed data. For
the secondary efficacy outcomes, change from
baseline in the ALSFRS-R was analyzed using the
same model as above.
The global null hypothesis for the primary and
secondary efficacy endpoints were tested in a pre-
specified order (as listed above) using a closed test-
ing procedure, and maintained the family-wise error
rate at two-sided significance level of 0.05 for all
hypotheses tested. No adjustment for multiplicity
was made for analyses of all reldesemtiv groups
pooled versus placebo, and subgroups defined by
patient characteristics that were post hoc exploratory;
all p values of statistical significance are nominal. An
estimated 445 patients had to be randomized to pro-
vide 90% power to detect a 2.75, 5.5, and 5.5 per-
centage point advantage over placebo for the 150mg
bid, 300mg bid, and 450mg bid reldesemtiv dose
groups, respectively, in change from baseline of per-
cent predicted SVC, at the end of the double-blind
period (week 12). This calculation was based on a
two-sided test with a set at 0.05 and an assumed
common standard deviation of 14%.
Results
Of the 605 patients screened, 458 were random-
ized to placebo (n¼115) or reldesemtiv 150mg bid
(n¼ 112), 300mg bid (n¼ 113), or 450mg bid
(n¼ 117) (one patient was randomized but with-
drew before treatment; Figure 1); 84.7% com-
pleted planned dosing. While early termination
from active treatment occurred at similar frequen-
cies in all groups, there was a tendency for
increased numbers of patients to withdraw from
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active treatment due to AEs as a function of
increased dose. However, early terminations due
to perceived disease progression were more com-
mon in the placebo group.
Patient characteristics in the reldesemtiv and
placebo groups are detailed in Table 1. Patients
were from the United States (n¼284), Canada
(n¼101), Spain (n¼38), Australia (n¼ 20), the
Netherlands (n¼11), and Ireland (n¼4). Baseline
demographics were well balanced, with no mean-
ingful differences among the 4 groups. The charac-
teristics resemble those of most previous and
current ALS trials, with the exception that time
from first symptom to screening was 22.8±19.1
months, which is longer than in many recent tri-
als.(6, 11–14) For some trials, symptom onset and
not time since diagnosis was the basis of the inclu-
sion criteria, which may contribute to at least
some of the differences related to this patient char-
acteristic.(11–14) In addition, 113/457 (24.7%) of
patients were on edaravone, either alone or in
combination with riluzole. Edaravone was used
only by patients in the United States and Canada.
Efficacy
The primary efficacy analysis of change from base-
line to week 12 in percent predicted SVC using
MMRM did not show a statistically significant
weighted dose-response relationship. Placebo-
treated patients showed a decline in vital capacity
of 6.46 percentage points at week 12, while the
patients treated with 150mg bid, 300mg bid, and
450mg bid reldesemtiv showed declines of 4.97
percentage points, 4.62 percentage points, and
4.58 percentage points, respectively (p¼0.11;
Figure 2(A)). Analyses of changes from baseline in
the ALSFRS-R Total Score (Figure 2(C)) and the
muscle strength mega-score (Figure 2(E)) using a
similar mixed model also did not reach statistical
significance (p¼0.09 for change from baseline to
week 12 in ALSFRS-R Total Score; p¼0.31 for
muscle strength mega-score slope from baseline
through week 12), although both measures showed
trends toward benefit at all doses. A post hoc com-
parison of all reldesemtiv-treated patients pooled
together versus placebo showed reductions in
decline by 27%, 25% and 21% for change from
baseline to week 12 in SVC, change from baseline
to week 12 in ALSFRS-R Total Score, and muscle
strength mega-score from baseline through 12
weeks (nominal p¼0.10, 0.01, and 0.20, respect-
ively; Figure 2(B,D,F). As seen in Figure 2, at the
week 16 visit, which was 4 weeks after the study
drug was stopped, there was a tendency for benefi-
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Figure 1. Patient disposition. All patients randomized contributed to the primary and secondary efficacy analyses, except for 1 patient
who withdrew consent right after randomization and did not receive any treatment in the placebo group; all dosed patients contributed
to the safety analysis. †2 patients were off study drug too long due to prolonged hospitalization. ‡1 patient no longer wanted to
participate in the study due to factors other than the study treatment or study procedures, 1 patient had difficulty traveling to clinic
visits, 1 patient withdrew for personal reasons. §1 patient could not continue the study and required visits due to unforeseen work
events, 1 patient withdrew due to family circumstances. ¶2 patients did not feel were benefiting from treatment and decided to
discontinue, 1 patient had difficulty traveling to clinic visits. AE: adverse event; bid: twice daily; ET: early termination.
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present for all three outcome measures, most not-
ably for SVC and ALSFRS-R.
Post hoc comparisons of all reldesemtiv groups
pooled versus placebo in subgroups defined by
various patient characteristics at baseline showed
that trends toward efficacy were seen with virtually
all subgroups across all three outcome measures,
and no subgroup appeared to be deleteriously
affected by reldesemtiv, suggesting that a potentially
beneficial effect of reldesemtiv was not driven by a
single patient group (Figure 3(A–C)). Overall,
patients appeared to benefit from reldesemtiv
regardless of edaravone or riluzole treatment dur-
ing the trial. There were no statistical differences
between patients receiving reldesemtiv (all doses
pooled) compared to the placebo group, irrespect-
ive of whether or not they were taking edaravone
or riluzole (p¼ 0.055 to 0.57); patients taking rilu-
zole and receiving reldesemtiv (all doses combined)
seemed to have a nominal statistical significant
reduction in the change in ALSFRS-R Total Score
at 12 weeks compared to placebo (p¼0.029). A
statistically significant reduction in the change in
ALSFRS-R at 12 weeks on reldesemtiv (all dose
levels pooled) versus placebo was observed among
patients who had ALS symptom onset less than 2
years prior to baseline (least squares [LS] mean
difference± standard error [SE] 1.4±0.5 for all
patients treated with reldesemtiv [n¼199] versus
placebo [n¼ 56]; p¼0.0025) (Figure 3(B)).
In post hoc analyses, outcomes were also eval-
uated by estimated rate of disease progression
using the date of symptom onset and the
ALSFRS-R Total Score at baseline. Patients were
sorted into tertiles: slowest (pretrial reduction of
ALSFRS-R Total Score 0.37 per month), middle
(>0.37–0.67 per month), and fastest (>0.67 per
month). In the fastest progressing tertile, there was
a statistically significant difference between all
reldesemtiv dose levels combined and placebo that
favored reldesemtiv in the change from baseline in
the ALSFRS-R (LS mean difference±SE
1.7±0.72 for all reldesemtiv-treated patients in that
tertile [n¼96] versus the placebo-treated patients
in that tertile [n¼30]; p¼ 0.018) (Figure 3(B)). In
the combined middle and fastest tertiles, change
from baseline in ALSFRS-R Total Score at week
12 was significantly smaller in patients who
received any dose of reldesemtiv versus placebo (LS
mean treatment difference 1.15, p¼ 0.011); no sig-
nificant difference between reldesemtiv and placebo
was observed in the slowest tertile (Figure 4(A)).
Changes from baseline in the ALSFRS-R Fine and
Gross Motor Domain scores showed a similar pat-
tern (Figure 4(B,C)); in the middle and fastest ter-
tiles, a significantly smaller change from baseline
in the ALSFRS-R Gross Motor Domain score at
week 12 was observed in patients treated with
reldesemtiv versus placebo (LS mean treatment dif-
ference 0.69, p¼0.0002).
Safety
Overall, reldesemtiv was well tolerated (Table 2).
Serious TEAEs were infrequent; a total of 34 ser-
ious TEAEs were equally distributed across all
treatment groups and organ systems. The most
common serious TEAEs (occurring in >1 patient)
regardless of attribution of relationship to study
drug are listed in Table 2. There was one death in
the placebo group during the 12 weeks of active
treatment, and two deaths in the 4-week follow-up
period (one in the placebo group, one in the relde-
semtiv 450mg bid group). There were six serious
TEAEs as defined by the principal investigator
that were attributed to study drug; the event terms
were hepatoxicity (two patients), alanine trans-
aminase increased (one patient), urinary retention
(one patient), transient ischemic attack (one1
patient) and one patient with increased aspartate













Age, y, mean (SD) 59.6 (10.6) 57.1 (10.9) 57.8 (10.2) 60.1 (11.0) 58.7 (10.7)
Male, n (%) 68 (59.1) 71 (63.4) 71 (62.8) 67 (57.3) 277 (60.6)
BMI, kg/m2, mean (SD) 26.1 (4.4) 26.9 (5.1) 26.2 (4.4) 27.1 (4.6) 26.6 (4.6)
eGFRCysC, mL/min/1.73m
2, mean (SD) 103 (18.1) 104 (16.3) 102 (16.8) 103 (17.3) 103 (17.1)
ALSFRS-R total score, mean (SD) 37.0 (5.6) 37.1 (5.5) 37.6 (5.6) 37.8 (5.5) 37.4 (5.5)
SVC, % predicted, mean (SD) 85.0 (14.8) 85.7 (14.8) 83.7 (14.5) 84.5 (17.1) 84.7 (15.3)
Months since diagnosis, mean (SD) 8.8 (6.3) 8.6 (6.4) 8.7 (6.1) 8.2 (5.6) 8.6 (6.1)
Months since 1st symptom, mean (SD) 22.1 (12.4) 23.9 (27.5) 22.5 (14.6) 22.7 (18.7) 22.8 (19.1)
ALS site of onset: bulbar, n (%) 22 (19.1) 18 (16.1) 17 (15.0) 30 (25.6) 87 (19.0)
ALS family history: yes, n (%) 12 (10.4) 15 (13.4) 12 (10.6) 14 (12.0) 53 (11.6)
On riluzole alone, n (%) 64 (55.7) 64 (57.1) 64 (56.6) 66 (56.4) 258 (56.5)
On edaravone alone, n (%) 5 (4.3) 5 (4.5) 4 (3.5) 5 (4.3) 19 (4.2)
On riluzole and edaravone, n (%) 24 (20.9) 22 (19.6) 24 (21.2) 24 (20.5) 94 (20.6)
ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; bid: twice daily; BMI: body mass index; eGFRCysC:
estimated glomerular filtration rate based upon cystatin C; SD: standard deviation; SVC: slow vital capacity.
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aminotransferase (AST), increased alanine amino-
transferase (ALT), increased creatinine kinase, and
decreased estimated glomerular filtration rate
(eGFR, which was based on cystatin C). Clinical
TEAEs were common, occurring in 403/457
(88%) patients. Except for fatigue and nausea,
which showed a dose-dependent pattern, events
were equally distributed across groups (Table 2).
There was no difference between active treatment
and the placebo arms regarding the Beck
Depression Inventory results or the Ashworth spas-
ticity scores (data not shown). No clinically rele-
vant abnormalities were observed in ECG
measurements during the 12-week active treatment
and 4-week follow-up periods.
There was a significant dose-dependent rela-
tionship noted in both increases in cystatin C and
decreases in eGFR determined by cystatin C, with
patients showing average reductions in eGFR from
baseline to week 12 of 9.2%, 11.2%, and 14.0% in
the reldesemtiv 150, 300, and 450mg bid dose
groups, respectively, compared with a small reduc-
tion of 2.1% on placebo. Mean eGFR declined to
an essentially stable level by 2 weeks of active
treatment and tended to recover after 4 weeks off
drug (Figure 5). Manifestations of renal toxicity
such as renal tubular casts or elevated urine pro-
tein were not seen. Decline in eGFR was the most
common reason for early termination of study
drug due to AEs, occurring in 7/457 (1.5%)
patients. Elevated ALT and AST of at least five
times the upper limit of normal were noted in a
dose-dependent manner, occurring in six patients,
four of whom were on 450mg bid of reldesemtiv
and one each on 150mg bid and 300mg bid. Four
of the six patients were also on riluzole. For these
six patients, when the drug was stopped, values
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Figure 2. LS mean change from baseline for each group from a mixed model analysis of (A) percent predicted SVC (primary
endpoint), (C) ALSFRS-R total score, and (E) muscle strength mega-score. Post hoc analysis of LS mean change from baseline from a
mixed model analysis for all reldesemtiv-treated patients versus placebo for (B) percent predicted SVC, (D) ALSFRS-R Total Score, and
(F) muscle strength mega-score. ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; bid, twice daily; BL:
baseline; LS: least squares; SE: standard error; SVC: slow vital capacity; wk: week.
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improving at the time of last follow-up for one
patient. Elevations in ALT and AST were reported
as TEAEs in 20/457 (4.4%) and 16/457 (3.5%)
patients, respectively (Table 2).
Pharmacokinetics
Plasma concentrations of reldesemtiv increased with
administration of higher dose levels. The highest
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Figure 3. Forest plots from post hoc analyses of LS mean differences between treatment with reldesemtiv and placebo by subgroups for
(A) percent predicted SVC, (B) ALSFRS-R, and (C) muscle strength mega-score. Pretrial reduction of ALSFRS-R total score per
month. ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; CI: confidence interval; LSM: least squares mean;
pbo: placebo SVC: slow vital capacity.
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dose time point at week 2 for all doses with geo-
metric mean±SE values of 1.05±1.07 lg/mL,
2.4±1.06 lg/mL, and 3.79±1.07 lg/mL for relde-
semtiv 150, 300, and 450mg bid, respectively.
Compared to a pharmacodynamic translational
study in which the common fibular nerve was
stimulated at varying frequencies in healthy partici-
pants and ankle dorsiflexion force was measured,
all three dose levels reached concentrations active
in that pharmacodynamic study (7).
Discussion
This phase 2b trial of reldesemtiv in patients with
ALS did not meet its pre-specified primary efficacy
analysis, despite trends toward efficacy in all func-
tional outcome measures at all dose levels. There
are several possible reasons unrelated to the intrin-
sic effect of reldesemtiv that might explain why the
primary endpoint was not reached. First, the pri-
mary outcome measure (SVC) in the placebo
group in this trial declined more slowly than in
most other ALS studies, due to inclusion criteria
enriching for slow progressors. Most ALS clinical
trials instead try to enrich rapid progressors and
have observed a decline in percent predicted SVC
of approximately 3 percentage points per month
(15–17). In this trial, the decline in SVC in the
placebo arm over 12 weeks was 6.46 percentage
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Figure 4. Post hoc analysis of change from baseline in (A) ALSFRS-R Total Score, (B) ALSFRS-R Fine Motor Domain and (C)
ALSFRS-R Gross Motor Domain score by progressor tertiles. ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-
Revised; FP: fastest progressors; LS: least squares; MP: middle progressors; SP: slowest progressors.
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interval. This slower than expected rate of decline
in percent predicted SVC reduced the ability to
demonstrate a statistically significant effect of relde-
semtiv on SVC. Second, the mixed model with
multiple contrasts employed in the primary ana-
lysis assumed a negligible effect of the lowest dose
(150mg bid) compared with the two higher doses.
As the lowest dose appeared to be active in all
three key efficacy measures, this multiple contrast
approach may not have been the best analysis to
demonstrate a treatment effect of reldesemtiv versus
placebo. Finally, this trial enrolled more slowly
progressing patients than several recent trials
(6, 11–14), which may have somewhat diluted an
efficacy signal by some patients not progressing
appreciably during the relatively short 12-week
duration of active treatment. Indeed, there
appeared to be clear evidence of benefit of relde-
semtiv among those patients progressing more rap-
idly prior to randomization and during the course
of the trial.
Results of this trial are consistent across the
three key outcome measures, all demonstrating
reductions in the rates of decline of 20% or more.
When a group of ALS experts was surveyed, slow-
ing of the rate of decline of the ALSFRS-R Total
Score by 20% was felt to be at least somewhat
clinically meaningful by 93% of respondents, and
slowing the decline by 25% or more was felt to be
at least somewhat clinically meaningful by 100%
of responding clinicians (18). It is unknown
whether the magnitude of effect of reldesemtiv will
continue to grow with time, but the curves for
both SVC and ALSFRS-R seem to be diverging at
12 weeks, so a maximum effect may not have
been reached.
With respect to ALSFRS-R, patients manifest-
ing more aggressive disease progression showed a
stronger treatment effect than those with more
slowly progressing disease. Nominally statistically
significant effects of treatment with reldesemtiv
were seen in the middle and fastest tertiles of pro-
gressors (based on the estimated pretrial rate of
disease progression) in both the ALSFRS-R Total
Score and ALSFRS-R Gross Motor Domain score
at week 12; numerically smaller decreases from
baseline were also observed following treatment
with reldesemtiv in the middle and fastest progres-
sors in ALSFRS-R Fine Motor Domain, percent
predicted SVC, and muscle strength mega-score at
week 12. Similarly, patients with symptoms of
ALS for less than 2 years or diagnosed for less
than 1 year showed a stronger treatment effect,
likely because this group includes fewer patients
Table 2. Most common TEAEs (10 patients in any treatment group), serious TEAEs (>1 patient), and deaths during the trial.











At Least One TEAE 97 (84.3) 100 (89.3) 98 (86.7) 108 (92.3) 403 (88.2)
Clinical Adverse Events
Fatigue 12 (10.4) 14 (12.5) 19 (16.8) 20 (17.1) 65 (14.2)
Nausea 14 (12.2) 10 (8.9) 13 (11.5) 22 (18.8) 59 (12.9)
Headache 15 (13.0) 16 (14.3) 16 (14.2) 11 (9.4) 58 (12.7)
Contusion 15 (13.0) 8 (7.1) 14 (12.4) 17 (14.5) 54 (11.8)
Dizziness 11 (9.6) 8 (7.1) 12 (10.6) 7 (6.0) 38 (8.3)
Constipation 5 (4.3) 7 (6.3) 13 (11.5) 10 (8.5) 35 (7.7)
Viral upper respiratory tract infection 9 (7.8) 6 (5.4) 10 (8.8) 9 (7.7) 34 (7.4)
Diarrhoea 8 (7.0) 12 (10.7) 7 (6.2) 4 (3.4) 31 (6.8)
Laboratory Adverse Events
Cystatin C increased 2 (1.7) 8 (7.1) 9 (8.0) 20 (17.1) 39 (8.5)
eGFR decreased 1 (0.9) 6 (5.4) 6 (5.3) 11 (9.4) 24 (5.3)
ALT increased 1 (0.9) 2 (1.8) 5 (4.4) 12 (10.3) 20 (4.4)
AST increased 1 (0.9) 2 (1.8) 3 (2.7) 10 (8.5) 16 (3.5)
At Least One Serious TEAE 10 (8.7) 8 (7.1) 8 (7.1) 8 (6.8) 34 (7.4)
Serious TEAEs
Dyspnoea 0 1 (0.9) 1 (0.9) 1 (0.9) 3 (0.7)
Urinary tract infection 1 (0.9) 1 (0.9) 1 (0.9) 0 3 (0.7)
ALT increased 0 0 0 2 (1.7) 2 (0.4)
Dysphagia 0 2 (1.8) 0 0 2 (0.4)
Hepatotoxicity 0 0 1 (0.9) 1 (0.9) 2 (0.4)
Pneumonia aspiration 2 (1.7) 0 0 0 2 (0.4)
Pulmonary embolism 2 (1.7) 0 0 0 2 (0.4)
Weight decreased 1 (0.9) 1 (0.9) 0 0 2 (0.4)
Deaths
ALS progression 1 (0.9) 0 0 1 (0.9) 2 (0.4)
Pulmonary embolism 1 (0.9) 0 0 0 1 (0.2)
Occurred during follow-up period.
ALS: amyotrophic lateral sclerosis; ALT: alanine aminotransferase; AST: aspartate aminotransaminase; bid: twice daily; eGFR:
estimated glomerular filtration rate; MedDRA: Medical Dictionary for Regulatory Activities; TEAE: treatment-emergent
adverse event.
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with more indolent disease. In contrast, the change
in percent predicted SVC in reldesemtiv-treated
patients (all doses pooled) compared to placebo
showed benefit favoring reldesemtiv in patients with
symptoms for at least 2 years and with diagnosis of
ALS for at least one year. This disparity may be
related to how these measures change over time;
ALSFRS-R decline generally follows a somewhat
curvilinear pattern but with decline occurring
throughout the disease (19), while SVC may be
relatively stable early in the disease (particularly
given the mean baseline SVC was 84.7±15.3%)
and start to decline later in the disease course
(20). Altogether, it appears more likely to demon-
strate an effect of reldesemtiv versus placebo in
patients who are more rapidly progressing on any
measure than in those who are not changing or are
worsening slowly. In fact, this reasoning formed
the basis for the stringent inclusion/exclusion crite-
ria adopted for the phase 3 edaravone trial aimed
at enriching for rapid progressors (21).
Importantly, the estimated effect size of reldesem-
tiv was not different between patients taking or not
taking either riluzole or edaravone, medications
approved for ALS, as shown by the non-statistically
significant p values for the treatment-by-existing
therapy interaction. At week 12, the impact of relde-
semtiv compared with placebo was similar regardless
of the use/no-use of riluzole or edaravone on percent
predicted change in SVC (treatment-by-riluzole use
interaction p¼0.90 and treatment-by-edaravone use
interaction p¼0.43), change in ALSFRS-R Total
Score (treatment-by-riluzole use interaction p¼ 0.56
and treatment-by-edaravone use interaction
p¼ 0.63), and muscle strength mega-score (treat-
ment-by-riluzole use interaction p¼0.87 and treat-
ment-by-edaravone use interaction p¼ 0.27,
respectively). As ALS is heterogeneous from the
pathogenesis standpoint, it is likely that effective
ALS treatment will require multiple medications in
combination, with any given medication exerting less
benefit than the combination. Our data suggest that,
should the efficacy of reldesemtiv be confirmed by a
pivotal phase 3 trial, it can be effectively combined
with existing approved therapies to provide ALS
patients with additional benefit.
Also of interest is the observation that 4 weeks
after active treatment was stopped, there was still a
trend toward benefit in all outcome measures. A
similar pattern was noted in the phase 2
BENEFIT-ALS trial of tirasemtiv in ALS, in which
the reduction in rate of decline in SVC was also
maintained 4 weeks after active treatment was dis-
continued. A similar persistence of effect 4 weeks
after the last dose of reldesemtiv was observed on
the 6min walk test in older children and adults
with spinal muscular atrophy (22). This effect can-
not be explained by the half-life of the drug or any
of its metabolites, so it may represent a disease-
modifying effect on either nerve or muscle. It is
possible that increasing muscle force and endur-
ance results in a muscle conditioning effect that
persists after stopping the study drug.
Alternatively, if peripheral nerves do not need to
fire as rapidly to achieve a given muscle force, one
can hypothesize that motor neuron function may
be preserved longer.
The safety and tolerability of reldesemtiv also
appear supportive of further development. While
clinical AEs were frequent, they were primarily
mild and, for the most part, balanced across treat-
ment groups. Nausea and fatigue occurred slightly
more frequently in active treatment arms but did
not limit continued use of the drug. The reduction
in eGFR (based on cystatin C) was clearly related
to dose. However, it was not progressive over
time, and tended toward resolution by 4 weeks
after stopping the study drug. The lack of indica-
tors of renal toxicity such as urinary casts or ele-
vated protein suggests that the eGFR change may
be a pharmacodynamic effect rather than true
nephrotoxicity. Similarly, elevations of transami-
nases more than five times the upper limit of nor-
mal were rare and normalized after the drug was
withdrawn. Overall, the safety findings do not
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In summary, reldesemtiv is well tolerated and
appeared to have a consistent trend toward reduc-
ing rates of decline across multiple measures of
ALS disease progression. Statistically significant
differences were not observed for the pre-specified
primary dose-response analyses of primary and
secondary endpoints, thus additional studies are
warranted to fully evaluate the effect and benefit of
reldesemtiv in patients with ALS. Its distinct mech-
anism of action makes it possible to use in com-
bination with existing and future ALS
therapeutics, and further development in a phase 3
trial is planned.
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